Edytujesz Użytkownik:Kato Beasley (sekcja)

== Commercial Experience and Research Collaboration ==

Aima Diagnostics has described a five-week commercial deployment in which the company reported that the repeat-visit rate increased from 12% to 16% after six months, average revenue per patient increased by 20%, and complaints about unclear results fell by half.

These figures are observations from a commercial case study, not controlled evidence that the technology improves clinical outcomes. Increased repeat visits or testing are not automatically beneficial; follow-up should be appropriate to the patient's needs.

The company also describes commercial, academic, and research collaborations across the United States, Scandinavia, the United Kingdom, Ukraine, and other European markets. Such collaborations may provide opportunities to examine technical integration, patient comprehension, workflow effects, and safety. A partnership or pilot, however, should not be confused with independent clinical validation.